Compare Krispy Kreme Inc (DNUT) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Krispy Kreme Inc vs Inovio Pharmaceuticals Inc — how do they compare? Krispy Kreme Inc trades at $3.01 (market cap $508.36M), while Inovio Pharmaceuticals Inc trades at $1.11 (market cap $119.42M). The key difference: Krispy Kreme Inc is far larger — about 4.3× Inovio Pharmaceuticals Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Krispy Kreme Inc for 45 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| DNUT | INO | |
|---|---|---|
Market Cap | $508.36M | $119.42M |
Volume | 1,955,706 | 2,789,649 |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $2.65 |
52-Week Low | $2.87 | $0.66 |
Typical Hold Time | 45 Days | 43 Days |
Enterprise Value | $1.75B | $90.75M |
Dividend Yield | 3.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $3.01, down 0.33% on the day, with a bearish technical signal. The company reported a net loss of $515.77 million in 2025, despite a 75.19% gross margin, and faces legal investigations into fiduciary duties. Revenue declined to $1.52 billion in 2025 from $1.7 billion in 2024.
The outlook is cautious due to persistent losses and legal overhangs, though analyst consensus leans buy. Key risks include profitability challenges and high debt. Upside depends on operational turnaround and new product launches driving growth.
INO trades at $1.09, down 3.54% on the day, with a bearish technical signal driven by moving averages. The company reported a net loss of $84.95 million in 2025 on minimal revenue of $65,340, with negative profitability metrics, but has beaten EPS estimates in recent quarters. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107.
The investment case hinges on regulatory approval of INO-3107, with a consensus price target of $2.75 implying significant upside. However, extreme financial losses, high cash burn, and dependence on dilutive financing pose substantial risks. Analyst sentiment is cautiously optimistic but reflects high uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
